Avicena ALS drug flunks Phase III trial

The Avicena Group of Palo Alto, CA, says its Phase III trial of ALS-02 for Lou Gehrig's disease failed to demonstrate a benefit over placebos. But researchers noted that data analysis demonstrated "a positive trend toward decreased mortality in subjects receiving ALS-02."

"We are very interested in further exploring this trend toward decreased mortality," said Belinda Tsao-Nivaggioli, Ph.D., Avicena's CEO. "We intend to explore whether these findings can be expected to impact the remaining regulatory path for the compound."

- here's the release for more information

Suggested Articles

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes.